- Spearheaded the development and execution of the Helix Immersion Programme (HIP), creating a pipeline of highly skilled talent for Singapore’s biomedtech and deep tech sectors and supported biomedtech companies in Singapore.- Fostered partnerships with government agencies, academic institutions and industry leaders, aligning training programs with the needs of biomedtech companies to ensure participants’ readiness for industry roles.- Championed talent retention strategies, successfully integrating local graduates into Singapore’s biomedtech ecosystem and aligning with industry demands to expand the talent pool.- Tailored the HIP to equip participants with both technical skills and business acumen, facilitating smooth transitions from academia to industry and boosting long-term employability in biomedtech.- Established mentorship programs and performance tracking, ensuring continuous development and alignment of participants with industry trends while enhancing the program’s effectiveness.

- Led Volition's business development efforts in the companion animal diagnostics market, driving the adoption of the Nucleosomics™ platform for non-invasive cancer detection in pets in Asia.- Cultivated strategic partnerships with veterinary clinics, animal hospitals, and diagnostic lab in Singapore to expand the availability of Volition's diagnostic tests for companion animals.- Conducted competitive market analysis within the veterinary diagnostics industry, identifying growth opportunities and positioning Volition’s products in Asia for the companion animal health market.- Represented Volition Veterinary Diagnostics at key veterinary conferences and industry forums, showcasing the benefits of Nucleosomics™ technology and driving awareness among veterinary professionals.

BTI Strategic Positioning- Plan and develop BTI mid-long term strategic initiatives and research budget with BTI leadership through development and implementation of BTI playbook- Identified 4 key growth areas and lead the formation of growth area interdisciplinary teams- Involved in programme shaping and building for Advanced Bionanalytical Tools in biologics development- Manage and engage BTI strategic key accounts for long term partnerships plan (incl. MNC's and SME's) - Inter-Research Institute, A*STAR HQ, and inter-agencies stakeholders engagementConflict Management Office (CMO)- Manage COI for BTI staff- Manage personnel conflict for BTI

Educated researchers on startup methodologies and oversaw biotech startup portfolio management, fostering innovation and entrepreneurship.

Bioprocessing Technology Institute:- Antibody Discovery PlatformTeam Lead for breast cancer Indication (human breast cancer and canine mammary cancer)Team Lead for human corneal endothelial isolation project Academic Achievements:Total number of publications: 15 Total Patents Filed/Granted: 8 (1 ophthalmology; 4 human oncology; 3 canine oncology)Competitive Grant No. Competitive Grant Secured: 2Total grant quatum: > SGD$2 million1) Involved in technology transfer and generation of lead targets-Successfully transferred both cell lines and technology from the industries to perform lab scale experiments -Generated >10 lead target for various projects currently targets are in preclinical evaluation stage- Preparation of research collaboration agreement (RCA) - Lead in development of business plans for spin-off for companion animal project2) Workstream Lead, Research Competency and Development Framework (RCDF)- Led a team of six researchers across diverse domains at A*STAR, driving initiatives under the Research Development Task Force (RDTF).- Designed and implemented platforms to enhance the growth, socialisation, and career development of researchers, fostering a collaborative and innovative research environment.- Streamlined processes and enhanced engagement strategies, contributing to a more integrated and supportive research community within A*STAR.

Bioprocessing Technology Institute :- Antibody Discovery Platform- Spearheaded the discovery of novel monoclonal antibodies against human cancers, contributing to the development of innovative therapeutics and diagnostics for breast and lung cancer.- Developed and patented monoclonal antibodies for human corneal endothelial cells, advancing alternative transplantation therapies and enhancing patient treatment options.

Bioprocessing Technology Institute :- Antibody Discovery Platform- Conducted groundbreaking research in the Antibody Discovery Platform, leading to the identification of novel monoclonal antibodies targeting human cancers, enhancing therapeutic options.- Developed innovative monoclonal antibodies for human corneal endothelial cells, contributing to advancements in alternative transplantation therapies.- Collaborated with multidisciplinary teams to streamline research protocols, resulting in increased efficiency and output in antibody development.- Published findings in peer-reviewed journals, significantly advancing the field of cancer therapeutics and regenerative medicine.

Strategy Planning - Developed and implemented strategic plans to enhance drug development processes, aligning project goals with organisational objectives.

Responsible for serum-free media development for human embryonics stem cells.

Responsible for managing and develop new accounts for industrial laundry detergent in Singapore.